Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boya is a multi-use name in the pharmaceutical and medical fields, primarily referring to a specific intravenous immunoglobulin (IVIG) product and a traditional herbal remedy. **Boya IVIG**, developed by Boya Bio-Pharmaceutical Group, is a plasma-derived biologic containing human IgG antibodies. It is currently in Phase 3 clinical development (e.g., NCT06150833) as a replacement therapy for patients with primary immunodeficiency diseases (PID), including common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), to maintain therapeutic IgG levels and prevent serious bacterial infections. Separately, **Badranj Boya** is the traditional name for the aromatic herb *Nepeta ruderalis* (Lamiaceae), which is used in traditional medicine for gastrointestinal and airway disorders. Research indicates that *Nepeta ruderalis* extracts possess spasmolytic and broncho-relaxant activities, likely mediated through the blockade of voltage-gated calcium channels. Additionally, the name Boya is associated with a brand of pulmonary calibration syringes, a multiplexing cold neutron spectrometer (BOYA), and geographic locations in Nepal.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Boya.